Urinary Bladder Cancer Clinical Trial
Official title:
Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Pilot Trial
Verified date | February 2024 |
Source | University of Kansas Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This single arm pilot study will evaluate the feasibility and acceptability for perioperative Comprehensive Geriatric Assessment (CGA) and CGA-directed supportive and restorative care for patients with muscle-invasive bladder cancer who are planned to undergo preoperative chemotherapy.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | August 21, 2023 |
Est. primary completion date | August 11, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: - Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent - Males and females age = 65 years - Diagnosis/disease status - Histologically proven muscle-invasive bladder cancer (MIBC) without metastatic disease. - Patients planning to undergo neoadjuvant chemotherapy and radical cystectomy for MIBC. - Treatment with investigational systemic therapy is permitted if participants will be receiving chemotherapy as part of their treatment plan Exclusion Criteria: - Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements - Any other known invasive malignancy within previous 2 years with the following EXCEPT: low grade prostate cancer on active surveillance, chronic lymphocytic leukemia CLL on surveillance / observation, non-melanoma skin cancers |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Kansas Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Develop a geriatric oncology assessment clinic and workflows | Develop a geriatric oncology assessment clinic and workflows for the University of Kansas Health System, including University of Kansas Cancer Center St. Francis and Great Bend practices. | 12 months | |
Secondary | Test feasibility, acceptability, and preliminary impact | Test feasibility, acceptability, and preliminary impact of the Comprehensive Geriatric Assessment (CGA) and CGA-directed care.
Note: The results of the CGA will be used by clinicians to guide patients' medical care. |
12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00872495 -
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
|
||
Completed |
NCT03998579 -
Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04525781 -
Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer
|
||
Completed |
NCT02897765 -
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
|
Phase 1 | |
Recruiting |
NCT05822934 -
Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer
|
Phase 3 | |
Completed |
NCT06156787 -
Patterns of Urinary Bladder Cancer in Darfur, Suda
|
||
Completed |
NCT02722538 -
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
|
Phase 1 | |
Completed |
NCT02437539 -
Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
|
Phase 1 | |
Completed |
NCT02139371 -
Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
|
Phase 0 | |
Completed |
NCT03433924 -
An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
|
||
Active, not recruiting |
NCT03132922 -
MAGE-A4ᶜ¹º³²T for Multi-Tumor
|
Phase 1 | |
Completed |
NCT05946369 -
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
|
||
Completed |
NCT00462488 -
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
|
Phase 2 | |
Recruiting |
NCT05621837 -
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
|
||
Recruiting |
NCT05644041 -
Intravesical Gemcitabine in Patients With NMIBC
|
Phase 2 | |
Completed |
NCT04635566 -
Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute
|
N/A | |
Recruiting |
NCT04861584 -
Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects
|
Phase 2 | |
Completed |
NCT01836978 -
Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy
|
N/A | |
Terminated |
NCT01374789 -
PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer
|
Phase 2 | |
Recruiting |
NCT03844256 -
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
|
Phase 1/Phase 2 |